Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat Sells 3,366 Shares

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat sold 3,366 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total value of $80,851.32. Following the completion of the transaction, the chief executive officer now owns 352,615 shares of the company’s stock, valued at approximately $8,469,812.30. The trade was a 0.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xencor Trading Down 0.5 %

XNCR stock traded down $0.11 during midday trading on Thursday, reaching $23.50. The company’s stock had a trading volume of 1,316,729 shares, compared to its average volume of 600,736. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -7.37 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $26.84. The stock has a fifty day simple moving average of $20.84 and a two-hundred day simple moving average of $20.37.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same period in the prior year, the business earned ($0.40) EPS. The firm’s quarterly revenue was down 81.9% on a year-over-year basis. On average, equities research analysts predict that Xencor, Inc. will post -3.79 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Darwin Global Management Ltd. acquired a new position in shares of Xencor during the first quarter worth $24,557,000. Logos Global Management LP grew its stake in Xencor by 130.8% during the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after buying an additional 850,000 shares during the last quarter. Braidwell LP acquired a new position in Xencor during the 3rd quarter valued at about $9,380,000. Point72 Asset Management L.P. raised its stake in Xencor by 52.9% in the second quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock valued at $23,886,000 after buying an additional 436,389 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Xencor by 9.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after acquiring an additional 335,881 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently commented on XNCR shares. Royal Bank of Canada boosted their price target on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. BMO Capital Markets restated an “outperform” rating and issued a $34.00 price objective (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wedbush reiterated an “outperform” rating and set a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Xencor has an average rating of “Moderate Buy” and a consensus price target of $35.75.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.